跳至主要内容
临床试验/NCT01747928
NCT01747928已完成1 期

A Representative Users Study Of The Operating Characteristics Of The Caverject Delivery System

Pfizer1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2013年3月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
48
试验地点
1
主要终点
Delivery System Success Rate (DSSR)

研究概览

简要总结

Usability testing of the dual-chambered syringe in conjunction with the proposed patient instructions for use.

详细描述

Usability testing of the dual-chambered syringe in conjunction with the proposed patient instructions for use

研究设计

研究类型
Interventional
干预模型
Parallel
盲法
None

入排标准

年龄范围
40 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者
是

入选标准

  • •Healthy males

排除标准

  • •Inability to read English;
  • •physical limitations preventing participant from operating the syringe

研究组 & 干预措施

Group 1

Experimental

干预措施: dual-chamber syringe (Other)

结局指标

主要结局

Delivery System Success Rate (DSSR)

时间窗: Day 1

DSSR was defined as percentage of participants who were able to successfully expel the selected dose from the Caverject Impulse Dual Chamber Delivery System when relying on the modified Instructions for Use (IFU). The process was considered successful if the attempt was observed and documented by study personnel AND the participant didn't receive any operational/"hands on" demonstration on how to operate the plunger from study personnel AND after performing all preparatory steps, the participant was able to expel the dose to the selected plunger stop-point without any unexpected interruption.

次要结局

  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q5(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q6(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q7(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q8(Day 1)
  • Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q9(Day 1)
  • Number of Participants With Categorical Responses to the Participant Assessment Tool (PAT): Instructions Provided Were Useful?(Day 1)
  • Number of Participants With Categorical Responses to the PAT: Instructions Provided Were Clear?(Day 1)
  • Number of Participants With Categorical Responses to the PAT: Most Difficult Step?(Day 1)
  • Number of Participants With Categorical Responses to the PAT: Syringe Easy to Use?(Day 1)
  • Number of Participants Providing Responses to Any Question on the PAT(Day 1)
  • Time Required to Perform Segments 1 to 5(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q1(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q2(Day 1)
  • Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q3(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q4(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q10(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q11(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q12(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q13(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q14b(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q16(Day 1)
  • Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q17(Day 1)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验